Why the study?
Do new direct and indirect acting factor Xa and thrombin inhibitors provide safe and effective alternatives to conventional anticoagulants for the prevention and treatment of thromboembolic disorders?
Do new direct and indirect acting factor Xa and thrombin inhibitors provide safe and effective alternatives to conventional anticoagulants for the prevention and treatment of thromboembolic disorders?
Answers are grounded in this paper and cite their sources.
Novel anticoagulants like rivaroxaban and dabigatran are emerging as approved alternatives to conventional anticoagulants, despite the safety failures of earlier agents and currently high cost-effectiveness ratios.
New direct and indirect acting factor Xa (FXa) and thrombin inhibitors are being developed to overcome the downsides of the conventional anticoagulants - unfractionated and low molecular weight heparins and vitamin K antagonists. Ximelagatran and idraparinux failed to demonstrate an acceptable safety profile. Rivaroxaban and dabigatran are approved for the post-operative prevention of thromboembolic complications after elective hip or knee replacement surgery; dabigatran is approved for the prevention of embolism in patients with atrial fibrillation in an increasing number of countries. Several novel indirect antithrombin-dependent anticoagulants as well as antithrombin-independent oral direct FXa and thrombin inhibitors are investigated in multiple indications for the prophylaxis and treatment of venous thromboembolism and the prophylaxis of arterial thrombotic disorders. Quality-adjusted life years costs and incremental cost-effectiveness ratios are relatively high at present, but may decrease after approval of more new anticoagulants for additional indications.
No takes yet. Share an insight, caveat, or question.
Harenberg et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: